Immunome Inc
IMNM10.300USD
+0.350+3.52%
收盘 08/22, 16:00（美东）报价延迟15分钟
896.23M总市值
亏损市盈率 TTM
关于 Immunome Inc 公司
Immunome, Inc. 是一家致力于开发靶向癌症疗法的生物技术公司。该公司的产品组合采用适合其生物学的模式来追求每个目标，包括免疫疗法、放射性配体疗法和抗体-药物偶联物 (ADC)。其记忆性 B 细胞杂交瘤技术可用于筛选和功能表征新型抗体和靶点。其项目包括肿瘤学 (IMM-ONC-01)、LU FAP 和 SARS-CoV-2 (IMM-BCP-01)。肿瘤学项目是一种针对白细胞介素-38 (IL-38) 的抗体 (IMM-ONC-01)，这是一种用于治疗各种实体瘤的新型免疫调节剂。其靶向效应器平台使用小分子配体选择性地将药物有效载荷递送至患病细胞。该公司还运营 AL102 和相关候选药物 AL101。AL102 是一种研究性小分子伽马分泌酶抑制剂，目前正在 III 期评估其用于治疗纤维瘤的效果。 AL102 是一种潜在的每日一次口服治疗纤维瘤的药物。
公司简介
公司代码IMNM
公司名称Immunome Inc
上市日期Oct 02, 2020
CEODr. Clay B. Siegall, Ph.D.
员工数量118
证券类型Ordinary Share
年结日Oct 02
公司地址18702 N. Creek Parkway
城市BOTHELL
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编98011
电话16103213700
网址https://immunome.com/
公司代码IMNM
上市日期Oct 02, 2020
CEODr. Clay B. Siegall, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Ms. Sandra G. Stoneman
Ms. Sandra G. Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Chief Legal Officer, General Counsel, Corporate Secretary
--
--
Dr. Phil Tsai
Dr. Phil Tsai
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Sandra M Swain, M.D.
Dr. Sandra M Swain, M.D.
Independent Director
Independent Director
--
--
Dr. Bob Lechleider, M.D.
Dr. Bob Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
收入明细
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
暂无数据
地区USD
名称
营收
占比
United States
2.93M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
9.51%
Fidelity Management & Research Company LLC
7.09%
BlackRock Institutional Trust Company, N.A.
5.94%
Redmile Group, LLC
5.60%
Enavate Sciences GP, LLC
5.48%
其他
66.39%
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
9.51%
Fidelity Management & Research Company LLC
7.09%
BlackRock Institutional Trust Company, N.A.
5.94%
Redmile Group, LLC
5.60%
Enavate Sciences GP, LLC
5.48%
其他
66.39%
股东类型
持股股东
占比
Investment Advisor
43.04%
Investment Advisor/Hedge Fund
24.45%
Hedge Fund
12.05%
Corporation
8.25%
Research Firm
5.75%
Individual Investor
1.69%
Venture Capital
0.89%
Bank and Trust
0.31%
Pension Fund
0.20%
其他
3.36%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
326
85.20M
99.48%
+13.79M
2025Q1
320
89.38M
113.71%
+17.13M
2024Q4
278
64.18M
84.45%
+3.64M
2024Q3
252
62.39M
103.49%
+7.38M
2024Q2
228
58.25M
97.90%
+16.13M
2024Q1
182
46.83M
84.41%
+22.74M
2023Q4
113
32.29M
78.79%
+19.76M
2023Q3
82
6.26M
40.47%
+930.23K
2023Q2
81
5.83M
36.98%
+582.43K
2023Q1
95
4.18M
34.54%
-644.30K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
T. Rowe Price Investment Management, Inc.
7.55M
8.68%
+2.05M
+37.36%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.89M
4.47%
-26.90K
-0.69%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.11M
5.87%
+1.37M
+36.49%
Mar 31, 2025
Redmile Group, LLC
5.36M
6.16%
+533.16K
+11.04%
Mar 31, 2025
Enavate Sciences GP, LLC
4.77M
5.48%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
4.36M
5.01%
+3.67M
+533.09%
Mar 31, 2025
The Vanguard Group, Inc.
4.29M
4.93%
+1.29M
+43.20%
Mar 31, 2025
EcoR1 Capital, LLC
4.08M
4.69%
+200.00K
+5.16%
Mar 31, 2025
Opaleye Management Inc.
3.55M
4.08%
+1.51M
+74.02%
Mar 31, 2025
PRIMECAP Management Company
3.41M
3.92%
+3.13M
+1115.71%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月6日 周三
更新时间: 8月6日 周三
机构名称
占比
Tema Oncology ETF
1.65%
iShares Genomics Immunology and Healthcare ETF
1.64%
WisdomTree BioRevolution Fund
1.01%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
ALPS Medical Breakthroughs ETF
0.55%
SPDR S&P Biotech ETF
0.2%
iShares Micro-Cap ETF
0.15%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
iShares Russell 2000 Growth ETF
0.05%
iShares US Tech Breakthrough Multisector ETF
0.04%
查看更多
Tema Oncology ETF
占比1.65%
iShares Genomics Immunology and Healthcare ETF
占比1.64%
WisdomTree BioRevolution Fund
占比1.01%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.86%
ALPS Medical Breakthroughs ETF
占比0.55%
SPDR S&P Biotech ETF
占比0.2%
iShares Micro-Cap ETF
占比0.15%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.13%
iShares Russell 2000 Growth ETF
占比0.05%
iShares US Tech Breakthrough Multisector ETF
占比0.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
